The Efficacy of External Beam Radiotherapy for Airway Obstruction in Lung Cancer Patients
Cancer Research and Treatment 2015³â 47±Ç 2È£ p.189 ~ p.196
:Lee Jeong-Won
:Lee Jong-Hoon/:Kim Hoon-Kyo/:Shim Byoung-Yong/:An Ho-Jung/:Kim Sung-Hwan
Abstract
Purpose: The objective of this study was to evaluate external beam radiotherapy (EBRT) in lung cancer patients who suffer from airway obstruction.
Materials and Methods: Medical data of 95 patients with a lung mass that obstructed the airway and received EBRT for it were analyzed. Fifty-nine patients (62.1%) had non-small cell lung cancer and 36 patients (37.9%) had small cell lung cancer. Radiotherapy was given at 8 to 45 Gy (median, 30 Gy) in 1 to 15 fractions (median, 10 fractions). The response to EBRT was assessed through changes in radiographic findings and/or subjective symptoms between before and after EBRT. The median follow-up duration was 124 days. The primary end point was the airway-obstruction resolving rate after EBRT. The secondary end points were patient survival and toxic effects of EBRT.
Results: Improvement of airway obstruction after EBRT on chest X-ray was achieved in 75 of 95 patients (78.9%). The median time for resolving the radiologic findings and/or symptoms of airway obstruction after EBRT was 7 days (range, 1 to 76 days). The 1-year survival rate was significantly higher in responders than non-responders (12.5% vs. 0.0%, p < 0.001). The biologically effective dose of ¡Ã 39 Gy¥á/¥â=10 (p < 0.01) and the longest obstructive lesion of < 6 cm (p=0.04) were significantly associated with a good response to EBRT in resolving the airway obstruction. No one had grade 3 or higher acute and chronic toxicities.
Conclusion: EBRT is an effective treatment in relieving airway obstruction without severe toxicities in lung cancer patients.
Å°¿öµå
Lung neoplasm, Radiotherapy, Airway obstruction
KMID :
0939920150470020189
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Improvement of airway obstruction after EBRT on chest X-ray was achieved in 75 of 95 patients (78.9%). The biologically effective dose of ¡Ã 39 Gy¥á/¥â=10 (p < 0.01) .